Negotiating Prices For Real-World Data Can Lower FDA Submission Costs, Shuren Says
This article was originally published in The Gray Sheet
Executive Summary
A new national evaluation system for devices will provide collective bargaining power to reduce the costs of real-world data to substitute for clinical trials in company submissions.